ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...

Please provide your email address to receive an email when new articles are posted on . Risk for death was lower with the pump vs. standard care only, but incidence of adverse events was elevated. The ...

In patients with ST-segment elevation myocardial infarction (STEMI)-induced cardiogenic shock undergoing hemodynamic monitoring with a pulmonary artery catheter, the use of a microaxial flow pump ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage. That is ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage. That is ...

DANVERS, Mass. – October 24, 2024 – Novel data on the benefits of Impella ® heart pump technology in high-risk percutaneous coronary intervention (PCI) and cardiogenic shock will be presented during ...

Results from the first randomized trial of Impella pumps during complex stent procedures, published in the New England Journal of Medicine, have shown that the pumps offer no significant benefit to ...

Results From The International MISSION Re-BEAT Feasibility Trial Using A Pulsatile, Soft Robotic Biventricular MCS Device That Avoids Blood Contact In Heart Failure Patients With Reduced Ejection ...

Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic ...